“The Predicting Effect of ASXL1 Mutation on BCR-ABL Transcript Types and Responses to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia” (2025) Medical Forum Monthly, 36(8). doi:10.60110/medforum.360805.